Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI-study: sacubitril/valsartan versus valsartan to arrest progression of nephropathy
2017-000213-23Phase 4Active
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan in chronic kidney disease (CKD), hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: 24-hour proteinuria reduction. Started Mar 2017; status: active.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-000213-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000213-23.